Cytokinetics, Incorporated (NASDAQ:CYTK)

Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates include omecamtiv mecarbil, a novel cardiac muscle myosin activator for the treatment of heart failure, which is in Phase I and IIb clinical trials; CK-2017357, a skeletal sarcomere activator for treating diseases or medical conditions associated with skeletal muscle weakness or wasting, which is in Phase II clinical trials; and CK-2127107, a skeletal sarcomere activator, which is in non-clinical stage. The company is also developing mitotic kinesin inhibitors, including ispinesib, SB-743921, and GSK-923295 for the treatment of cancer. The company has a strategic alliance with Amgen Inc. to discover, develop, and commercialize small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.

Last updated March 6, 2013